» Articles » PMID: 30534046

Kinetic Modeling of PH-Dependent Oxidation of Dopamine by Iron and Its Relevance to Parkinson's Disease

Overview
Journal Front Neurosci
Date 2018 Dec 12
PMID 30534046
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease is the second most common neurodegenerative disease. While age is the most significant risk factor, the exact cause of this disease and the most effective approaches to mitigation remain unclear. It has long been proposed that dopamine may play a role in the pathology of Parkinson's disease in view of its ability to generate both protein-modifying quinones such as aminochrome and reactive oxygen species, especially in the presence of pathological iron accumulation in the primary site of neuron loss. Given the clinically measured acidosis of Parkinson's disease brain tissue, the interaction between dopamine and iron was investigated over a pH range of 7.4 to 6.5 with emphasis on the accumulation of toxic quinones and generation of reactive oxygen species. Our results show that the presence of iron accelerates the formation of aminochrome with ferrous iron (Fe[II]) being more efficient in this regard than ferric iron (Fe[III]). Our results further suggest that a reduced aminochrome rearrangement rate coupled with an enhanced turnover rate of Fe[II] as a result of brain tissue acidosis could result in aminochrome accumulation within cells. Additionally, under these conditions, the enhanced redox cycling of iron in the presence of dopamine aggravates oxidative stress as a result of the production of damaging reactive species, including hydroxyl radicals.

Citing Articles

Amphetamine-like Deferiprone and Clioquinol Derivatives as Iron Chelating Agents.

El Safadi M, Wilson K, Strudwicke I, OMara M, Bhadbhade M, Rawling T Molecules. 2024; 29(17).

PMID: 39275060 PMC: 11397356. DOI: 10.3390/molecules29174213.


Oxidation of dopamine and related catechols in dopaminergic brain regions in Parkinson's disease and during ageing in non-Parkinsonian subjects.

Fornstedt Wallin B J Neural Transm (Vienna). 2024; 131(3):213-228.

PMID: 38238531 DOI: 10.1007/s00702-023-02718-2.


pH jump kinetics in colliding microdroplets: accelerated synthesis of azamonardine from dopamine and resorcinol.

Brown E, Rovelli G, Wilson K Chem Sci. 2023; 14(23):6430-6442.

PMID: 37325131 PMC: 10266468. DOI: 10.1039/d3sc01576a.


Interaction and Redox Chemistry between Iron, Dopamine, and Alpha-Synuclein C-Terminal Peptides.

Schifano F, DellAcqua S, Nicolis S, Casella L, Monzani E Antioxidants (Basel). 2023; 12(4).

PMID: 37107166 PMC: 10135331. DOI: 10.3390/antiox12040791.


The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease.

Nagatsu T, Nakashima A, Watanabe H, Ito S, Wakamatsu K, Zucca F J Neural Transm (Vienna). 2023; 130(5):611-625.

PMID: 36939908 PMC: 10121510. DOI: 10.1007/s00702-023-02617-6.


References
1.
Sampson T, Debelius J, Thron T, Janssen S, Shastri G, Ilhan Z . Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. Cell. 2016; 167(6):1469-1480.e12. PMC: 5718049. DOI: 10.1016/j.cell.2016.11.018. View

2.
Hare D, Double K . Iron and dopamine: a toxic couple. Brain. 2016; 139(Pt 4):1026-35. DOI: 10.1093/brain/aww022. View

3.
Sun Y, Pham A, Waite T . The effect of vitamin C and iron on dopamine-mediated free radical generation: implications to Parkinson's disease. Dalton Trans. 2018; 47(12):4059-4069. DOI: 10.1039/c7dt04373b. View

4.
Burbulla L, Song P, Mazzulli J, Zampese E, Wong Y, Jeon S . Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. Science. 2017; 357(6357):1255-1261. PMC: 6021018. DOI: 10.1126/science.aam9080. View

5.
Jian N, Dowle M, Horniblow R, Tselepis C, Palmer R . Morphology of the ferritin iron core by aberration corrected scanning transmission electron microscopy. Nanotechnology. 2016; 27(46):46LT02. DOI: 10.1088/0957-4484/27/46/46LT02. View